R Retreatment in 1st Relapsed DLBCL
|ClinicalTrials.gov Identifier: NCT00980304|
Recruitment Status : Unknown
Verified September 2009 by Shanghai Jiao Tong University School of Medicine.
Recruitment status was: Not yet recruiting
First Posted : September 21, 2009
Last Update Posted : September 21, 2009
It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients after 1st line induction treatment of 6~8 cycles of RCHOP-like chemo will be enrolled to receive 3 cycles of RICE as salvage therapy.
After treatment each patient should be followed up for 2 years.
|Condition or disease||Intervention/treatment||Phase|
|Lymphomas||Drug: Rituximab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Multicenter, Open Label, Phase II Trial of Rituximab in Combination With ICE as Salvage Therapy in the Relapsed DLBCL Patients After 1st Line Induction Treatment of 6-8 Cycles of RCHOP-LIKE Chemo|
|Experimental: Rituximab in combination with ICE as salvage therapy||Drug: Rituximab|